Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Atara Biotherapeutics, Inc. granted 3,750 restricted stock units to a new employee under the 2018 Inducement Plan. The units vest over four years, subject to continuous employment.

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported the grant of 3,750 restricted stock units of Atara’s common stock to one newly hired employee. This award was approved by the Compensation Committee of Atara’s Board of Directors and granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan, with a grant date of April 1, 2024, as an inducement material to the new employee entering into employment with Atara, in accordance with Nasdaq Listing Rule 5635(c)(4).

The restricted stock units vest over four years, with 25 percent vesting on the first quarterly vesting date after the first anniversary of the vesting commencement date and the remainder vesting in 12 approximately equal quarterly installments over the following three years, subject to the employee being continuously employed by Atara as of such vesting dates.

Atara is providing this information in accordance with Nasdaq Listing Rule 5635(c)(4).

About Atara Biotherapeutics, Inc.

Atara is harnessing the natural power of the immune system to develop off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions that can be rapidly delivered to patients from inventory. With cutting-edge science and differentiated approach, Atara is the first company in the world to receive regulatory approval of an allogeneic T-cell immunotherapy. Our advanced and versatile T-cell platform does not require T-cell receptor or HLA gene editing and forms the basis of a diverse portfolio of investigational therapies that target EBV, the root cause of certain diseases, in addition to next-generation AlloCAR-Ts designed for best-in-class opportunities across a broad range of hematological malignancies and B-cell driven autoimmune diseases. Atara is headquartered in Southern California. For more information, visit atarabio.com and follow @Atarabio on X and LinkedIn.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240405217863/en/

Investor and Media Relations

Jason Awe, Ph.D.

Senior Director, Corporate Communications & Investor Relations

(805) 217-2287

jawe@atarabio.com

Source: Atara Biotherapeutics, Inc.

FAQ

What is the ticker symbol for Atara Biotherapeutics, Inc.?

The ticker symbol for Atara Biotherapeutics, Inc. is ATRA.

How many restricted stock units were granted to the new employee?

Atara Biotherapeutics, Inc. granted 3,750 restricted stock units to the new employee.

Under which plan were the restricted stock units granted?

The restricted stock units were granted under the Atara Biotherapeutics, Inc. 2018 Inducement Plan.

How long does it take for the restricted stock units to vest?

The restricted stock units vest over four years.

What is the vesting schedule for the restricted stock units?

25 percent of the units vest on the first quarterly vesting date after the first anniversary, with the remainder vesting in approximately equal quarterly installments over the following three years.

What is the grant date for the restricted stock units?

The grant date for the restricted stock units is April 1, 2024.